Inactive Instrument

News Verona Pharma Plc London S.E.

Equities

GB00B06GSH43

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Jul. 16	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
Jul. 15	European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Jul. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	Jul. 15	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	Jul. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Jul. 03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Jul. 02	MT
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre, First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years	Jun. 28	AQ
Truist Securities Raises Price Target on Verona Pharma to $38 From $32, Maintains Buy Rating	Jun. 27	MT
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	Jun. 27	MT
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month	Jun. 27	RE
Verona Pharma Announces US FDA Approval of Ohtuvayre	Jun. 27	AQ
Transcript : Verona Pharma plc - Special Call	Jun. 27
HC Wainwright Adjusts Price Target on Verona Pharma to $36 From $32, Maintains Buy Rating	Jun. 27	MT
Verona Pharma Gets FDA Nod for Pulmonary Disease Treatment; Shares Jump Premarket	Jun. 27	MT
The same old winners	Jun. 27
Verona Pharma Gets US FDA Approval for Ohtuvayre in Chronic Obstructive Pulmonary Disease	Jun. 26	MT
FDA approves Verona Pharma's therapy for 'smoker's lungs'	Jun. 26	RE
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)	Jun. 26	AQ
Verona Pharma Announces US FDA Approval of Ohtuvayre (Ensifentrine)	Jun. 26	CI
Verona Pharma's Maintenance Treatment for Chronic Obstructive Pulmonary Disease Gets FDA Approval	Jun. 26	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	Jun. 25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Verona Pharma Plc London S.E.

Equities

GB00B06GSH43

Summary

Filters